4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-19-050606
Chief Executive Officer sold 112,650 shares at an average $28.54 ($3,215,055)
- Chief Executive Officer acquired 112,650 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Anzalone Christopher Richard · Chief Executive Officer
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2019-09-20 | Exercise or conversion : show line 1 in the form | +4,250 | $5.10 | $21,675 | 2,146,153 | D |
| 2019-09-20 | Sale : show line 2 in the form | −4,250 | $29.00 | $123,250 | 2,141,903 | D |
| 2019-09-23 | Exercise or conversion : show line 3 in the form | +41,755 | $5.10 | $212,951 | 2,183,658 | D |
| 2019-09-23 | Sale : show line 4 in the form | −41,755 | $29.04 | $1,212,565 | 2,141,903 | D |
| 2019-09-24 | Exercise or conversion : show line 5 in the form | +66,645 | $5.10 | $339,890 | 2,208,548 | D |
| 2019-09-24 | Sale : show line 6 in the form | −53,972 | $28.00 | $1,511,216 | 2,154,576 | D |
| 2019-09-24 | Sale : show line 7 in the form | −12,673 | $29.04 | $368,024 | 2,141,903 | D |
| Open-market sales · 112,650 sh · avg $28.54 · $3,215,055 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2019-09-20 | Exercise or conversion : show line 8 in the form Stock Option (right to buy) | −4,250 | 1,110,268 | D |
| 2019-09-23 | Exercise or conversion : show line 9 in the form Stock Option (right to buy) | −41,755 | 1,068,513 | D |
| 2019-09-24 | Exercise or conversion : show line 10 in the form Stock Option (right to buy) | −66,645 | 1,001,868 | D |
Loading xslF345X03/doc4.xml…